RASopathies, such as cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, are rare developmental diseases caused by germline mutations that lead to overactivation of the RAS-MAPK pathway. Anastasaki et al. build on previous work to test whether fine-tuning doses of PD0325901, an inhibitor of this pathway that is in clinical use for cancer treatment, can minimise the developmental defects of RASopathies. Using zebrafish embryos, they show that continuous, low doses of PD0325901 during development prevents the detrimental effects of a CFC-associated mutation without inducing the side effects observed when inhibiting the pathway using higher doses of the drug. Thus, anti-cancer agents that target the RAS-MAPK pathway might hold promise for these devastating developmental diseases. Page 546
Skip Nav Destination
IN THIS ISSUE| 01 July 2012
Fine-tuning candidate therapy for RASopathies
Online ISSN: 1754-8411
Print ISSN: 1754-8403
Written by editorial staff. © 2012. Published by The Company of Biologists Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Share Alike License (http://creativecommons.org/licenses/by-nc-sa/3.0), which permits unrestricted non-commercial use, distribution and reproduction in any medium provided that the original work is properly cited and all further distributions of the work or adaptation are subject to the same Creative Commons License terms
Dis Model Mech (2012) 5 (4): 413.
Fine-tuning candidate therapy for RASopathies. Dis Model Mech 1 July 2012; 5 (4): 413. doi:
Download citation file: